Robert D. Allen
Chief Scientific OfficerDr. Robert D. Allen, Ph. D., served as Senior Vice President of R&D at Sorrento Therapeutics, Inc. since 2022 until April 2023 and served as its Senior Vice President of Antiviral & Immunotherapy since November 2020 until 2022. He serves as Chief Scientific Officer at Invivyd, Inc. since April 11, 2023. He serves as Chief Science Officer at SmartPharm Therapeutics, Inc. Dr. Allen was in the biotechnology industry leading research, preclinical development, and early clinical manufacturing of antiviral and anti-cancer therapeutics. Prior to joining Sorrento, Dr. Allen served as Scientific Director of the Oregon Translational Research and Development Institute (OTRADI), collaborating with industry and academic Partners on drug discovery and candidate profiling campaigns targeting hematologic cancers, solid tumors, and infectious disease pathogens. He brings wide exposure. Prior to OTRADI, Dr. Allen developed discovery programs at SIGA Technologies that identified direct-Acting antivirals targeting viruses in the bunyavirus and filovirus families as well as host-directed countermeasures against a broad spectrum of human viruses and obligate intracellular bacteria. Dr. Allen earned a Ph. D. in microbiology from Columbia University Vagelos College of Physicians and Surgeons, a M. S. in applied biology from Georgia Institute of Technology, and a B. S. in biology from Rhodes College.
Positions
- Company NameInvivyd, Inc.Stock CodeIVVDPositionChief Scientific OfficerColleagues
- MWMarc William EliaCEO & Chairperson of the Board
- WEWilliam E. DukeCFO and Principal Financial & Accounting Officer
- JAJill AndersenChief Legal Officer & Corporate Secretary
- TLTimothy LeeChief Commercial Officer
- AGAjay Gopal RoyanLead Independent Director
- KFKevin F. McLaughlinIndependent Director
- TGTerrance G. McGuireIndependent Director
- TBTamsin BerryIndependent Director
